{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:17:46Z","timestamp":1778199466236,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study examined temporal shifts in adjuvant therapy patterns in Japanese patients with resectable gastric cancer (GC) and treatment patterns of first-line and subsequent therapy among those with recurrent disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective analysis of hospital-based administrative claims data (April 1, 2008 to March 31, 2022) included adults (aged\u2009\u2265\u200920\u00a0years) with GC who started adjuvant therapy on or after October 1, 2008 (adjuvant cohort) and patients in the adjuvant cohort with disease recurrence (recurrent cohort), further defined by the time to recurrence (\u2264\u2009180 or\u2009&gt;\u2009180\u00a0days after adjuvant therapy).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the adjuvant cohort (n\u2009=\u200917,062), the most common regimen during October 2008\u2013May 2016 was tegafur\/gimeracil\/oteracil potassium (S-1; 95.7%). As new standard adjuvant regimen options were established, adjuvant S-1 use decreased to 65.0% and fluoropyrimidine plus oxaliplatin or docetaxel plus S-1 use increased to 15.0% and 20.0%, respectively, in September 2019\u2013March 2022. In the recurrent cohort with no history of trastuzumab\/trastuzumab deruxtecan treatment (n\u2009=\u20091257), the most common first-line regimens were paclitaxel plus ramucirumab (34.0%), capecitabine plus oxaliplatin (CapeOX; 17.0%), and nab-paclitaxel plus ramucirumab (10.1%) in patients with early recurrence, and S-1 plus oxaliplatin (26.3%), S-1 plus cisplatin (15.3%), CapeOX (14.0%), S-1 (13.2%), and paclitaxel plus ramucirumab (10.8%) in those with late recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study demonstrated temporal shifts in adjuvant treatment patterns that followed the establishment of novel regimens, and confirmed that post-recurrent treatment patterns were consistent with the Japanese Gastric Cancer Association guideline recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-024-01501-w","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:02:54Z","timestamp":1714521774000},"page":"827-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in Japan: a retrospective database cohort study"],"prefix":"10.1007","volume":"27","author":[{"given":"Takaki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yorifumi","family":"Kikko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kimijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Casaes Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Tejada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-231X","authenticated-orcid":false,"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"1501_CR1","unstructured":"National Cancer Center (2022) Projected cancer statistics https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html Accessed Jun 20 2023"},{"issue":"26","key":"1501_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"2023","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines, 6th edition. Gastric Cancer. 2021;2023(26):1\u201325.","journal-title":"Gastric Cancer"},{"key":"1501_CR3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1501_CR4","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"1501_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321.","journal-title":"Lancet"},{"key":"1501_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","volume":"32","author":"SH Park","year":"2021","unstructured":"Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32:368\u201374.","journal-title":"Ann Oncol"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10120-011-0020-x","volume":"14","author":"T Aoyama","year":"2011","unstructured":"Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, et al. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14:150\u20134.","journal-title":"Gastric Cancer"},{"key":"1501_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1159\/000317762","volume":"56","author":"H Hasegawa","year":"2010","unstructured":"Hasegawa H, Fujitani K, Kurokawa Y, Hirao M, Nakazuru S, Mita E, et al. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer. Chemotherapy. 2010;56:436\u201343.","journal-title":"Chemotherapy"},{"key":"1501_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-011-0101-x","volume":"15","author":"K Shitara","year":"2012","unstructured":"Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, et al. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer. 2012;15:245\u201351.","journal-title":"Gastric Cancer"},{"issue":"24","key":"1501_CR11","first-page":"1","volume":"2021","author":"Japanese Gastric Cancer Association","year":"2018","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines, 5th edition. Gastric Cancer. 2018;2021;24:1\u201321.","journal-title":"Gastric Cancer"},{"key":"1501_CR12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139.","journal-title":"Lancet Oncol"},{"key":"1501_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1501_CR14","unstructured":"Foundation for Promotion of Cancer Research (2023) Cancer statistics in Japan\u20132023 [in Japanese]. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2023_data_E.pdf. Accessed 21 Jun 2023"},{"key":"1501_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101980","volume":"85","author":"N Joharatnam-Hogan","year":"2020","unstructured":"Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat Rev. 2020;85:101980.","journal-title":"Cancer Treat Rev"},{"key":"1501_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40801-022-00331-5","volume":"9","author":"J Fujinaga","year":"2022","unstructured":"Fujinaga J, Fukuoka T. A review of research studies using data from the administrative claims databases in Japan. Drugs Real World Outcomes. 2022;9:543\u201350.","journal-title":"Drugs Real World Outcomes"},{"key":"1501_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","volume":"39","author":"Y Komatsu","year":"2022","unstructured":"Komatsu Y, Hironaka S, Tanizawa Y, Cai Z, Piao Y, Boku N. Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: a retrospective administrative claims database study. Adv Ther. 2022;39:296\u2013313.","journal-title":"Adv Ther"},{"key":"1501_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:1\u201311.","journal-title":"J Epidemiol"},{"key":"1501_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3109\/09638288809164105","volume":"10","author":"DT Wade","year":"1988","unstructured":"Wade DT, Collin C. The barthel ADL index: a standard measure of physical disability? Int Disabil Stud. 1988;10:64\u20137.","journal-title":"Int Disabil Stud"},{"key":"1501_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","volume":"13","author":"E Otto","year":"2022","unstructured":"Otto E, Culakova E, Meng S, Zhang Z, Xu H, Mohile S, et al. Overview of sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer. J Geriatr Oncol. 2022;13:742\u20136.","journal-title":"J Geriatr Oncol"},{"key":"1501_CR21","unstructured":"National Cancer Center (2021) In-hospital cancer registry [in Japanese] https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/pdf\/2021_report_02.pdf Accessed 21 Jun 2023"},{"key":"1501_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30:830\u20138.","journal-title":"Ann Oncol"},{"key":"1501_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00155","volume":"3","author":"M Stewart","year":"2019","unstructured":"Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1\u201315.","journal-title":"JCO Clin Cancer Inform"},{"key":"1501_CR24","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1002\/cam4.2420","volume":"8","author":"G Yang","year":"2019","unstructured":"Yang G, Ma D, Xu H, Yang L, Li J, Xing P, et al. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: a retrospective, real-world study. Cancer Med. 2019;8:5823\u201330.","journal-title":"Cancer Med"},{"key":"1501_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10120-018-0815-0","volume":"21","author":"K Nishikawa","year":"2018","unstructured":"Nishikawa K, Tsuburaya A, Yoshikawa T, Takahashi M, Tanabe K, Yamaguchi K, et al. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Gastric Cancer. 2018;21:811\u20138.","journal-title":"Gastric Cancer"},{"key":"1501_CR26","doi-asserted-by":"publisher","first-page":"S1390","DOI":"10.1016\/j.annonc.2023.09.139","volume":"34","author":"A Makiyama","year":"2023","unstructured":"Makiyama A, Shoji H, Kawakami H, Tamura T, Sugiyama K, Hara H, et al. O14\u20131 A randomized phase II study of S-1 monotherapy and S-1\/L-OHP combination (SOX) therapy for unresectable\/recurrent gastric cancer in the elderly [JSMO abstract]. Ann Oncol. 2023;34:S1390.","journal-title":"Ann Oncol"},{"key":"1501_CR27","unstructured":"Pharmaceuticals and Medical Devices Agency (2021) New drugs approved in FY 2021. https:\/\/www.pmda.go.jp\/files\/000267878.pdf. Accessed 19 Apr 2024"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01501-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-024-01501-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01501-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T07:04:54Z","timestamp":1721286294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-024-01501-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s10120-024-01501-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Grammatical errors in the article title and article note were corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Takaki Yoshikawa has received lecture fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd, Medtronic Japan Co., Ltd., Bristol-Myers Squibb K.K., EA Pharma Co., Ltd., Johnson & Johnson K.K., AstraZeneca K.K., Intuitive Surgical, Inc., Japan Blood Products Organization, Olympus, Eli Lilly Japan K.K., and Astellas Pharma Inc. Yorifumi Kikko has received medical writing\/editorial support from Bristol-Myers Squibb K.K., and Ono Pharmaceutical Co., Ltd.; and is an employee of Bristol-Myers Squibb K.K. Reina Makino is an employee of Ono Pharmaceutical Co., Ltd. Yuya Kimijima is an employee of Bristol-Myers Squibb K.K. Eiji Nishiyama and Yuko Matsuda are employees of Ono Pharmaceutical Co., Ltd. Bruno Casaes Teixeira is an employee of and holds stock or stock options in Bristol Myers Squibb. Mariella Tejada is an employee of Bristol Myers Squibb. Robert Carroll is an employee of Bristol Myers Squibb. Dr. Shuichi Hironaka has received consulting fees from Astellas; and has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., Yakult Honsha Co., Ltd., and Bayer Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures followed were in accordance with the principles of the Helsinki Declaration of 1964 and later versions, the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices and regulations associated with scientific and medical research involving human subjects in Japan. Ethics committee review and approval prior to study initiation were not required because the MDV database had undergone extensive ethical review and approval in relation to contracts with individual hospital data providers. Because data elements in the MDV database have been de-identified, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}